Valneva
jumps on positive results for COVID-19 vaccine candidate
Send a link to a friend
[October 18, 2021]
PARIS (Reuters) -Valneva reported positive
Phase III results on Monday for its inactivated, adjuvanted COVID-19
vaccine candidate VLA2001, lifting its shares in a boost for the French
biotech company after Britain cancelled a big deal to buy its shot.
|
Valneva said its latest trial, on 4,012 participants aged 18 and
older across 26 trial sites in Britain, showed the vaccine prompted
a stronger immune response and fewer side-effects than AstraZeneca's
shot.
The update fuelled a jump of 37.5% in early session trading of
Valneva's shares, which had fallen sharply in September after the
cancellation.
Valneva is among a handful of vaccine developers testing their
vaccines against one already approved by a regulator, rather than
giving volunteers a placebo as shots become more available.
"These results confirm the advantages often associated with
inactivated whole virus vaccines," said Chief Executive Thomas
Lingelbach, adding that the company believed it would make an
important contribution to the fight against COVID-19.
Valneva said it was preparing for trials in children aged 5 to 12
and for a Valneva-sponsored trial to evaluate VLA2001's performance
for those in need of a vaccine booster shot.
[to top of second column] |
![](http://archives.lincolndailynews.com/2021/Oct/18/images/ads/current/state_bank_lda_PPP_2021.png) Its shares plunged last month
after Britain scrapped a contract for about 100
million doses of the vaccine Valneva was
developing, partly over concerns about when it
would win approval.
Valneva has been expanding the trials of its
VLA2001 COVID-19 vaccine candidate, and remains
in talks with the European Commission over a
potential contract.
(Reporting by Sudip Kar-Gupta; Editing by
Krishna Chandra Eluri and Clarence Fernandez)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content |